Taylor & Francis Group
Browse
tbeq_a_1775118_sm3351.pdf (144.18 kB)

Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens

Download (144.18 kB)
Version 2 2020-06-17, 07:02
Version 1 2020-06-05, 11:22
journal contribution
posted on 2020-06-17, 07:02 authored by Georgi Momekov, Denitsa Momekova

The broad-spectrum antiparasitic agent ivermectin has been very recently found to inhibit SARS-CoV-2 in vitro and proposed as a candidate for drug repurposing in COVID-19. In the present report the in vitro antiviral activity end-points are analyzed from the pharmacokinetic perspective. The available pharmacokinetic data from clinically relevant and excessive dosing studies indicate that the SARS-CoV-2 inhibitory concentrations are not likely to be attainable in humans.

History

Usage metrics

    Biotechnology & Biotechnological Equipment

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC